Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

international pharmaceutical services sa-nv - mesalazine 500 mg - gastro-resistant tablet - 500 mg - mesalazine 500 mg - mesalazine

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - mesalazine 500 mg - gastro-resistant tablet - 500 mg - mesalazine 500 mg - mesalazine

Australia - inglés - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 4 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; ethylcellulose; povidone; microcrystalline cellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 2 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - granules, modified release - excipient ingredients: ethylcellulose; povidone - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - mesalazine - enema - 10mg/1ml

Australia - inglés - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mesalazine, quantity: 250 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; povidone; sodium carbonate; purified talc; titanium dioxide; iron oxide red; colloidal anhydrous silica; calcium stearate; glycine; iron oxide yellow; methacrylic acid copolymer; macrogol 6000; triethyl citrate - indications as at 12 september 1990: treatment of acute inflammatory large bowel disease. maintenance therapy of crohns colitis and ulcerative colitis in patients sensitive to sulfasalazine.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - granules, modified release - excipient ingredients: simethicone; aspartame; microcrystalline cellulose; triethyl citrate; colloidal anhydrous silica; citric acid; carmellose sodium; magnesium stearate; purified talc; titanium dioxide; povidone; methacrylic acid copolymer; hypromellose; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.